SequelSEC

IMPACT BIOMEDICAL INC. IBO

Pharmaceutical Preparations · CIK 0001834105 · Fiscal year ends 1231

Revenue
$32.00K
Fiscal year ended 2025-12-31
Operating income
-$4.28M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$7.60MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.07Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue237.5×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin-1225.0%1th
Net margin-36993.8%7th
Current ratio0.35x9th
Operating margin-13381.2%9th
R&D / revenue1062.5%75th
SBC / revenue40.6%58th

IMPACT BIOMEDICAL INC. (IBO) reported revenue of $32.00K and net income of -$11.84M for the fiscal year ended 2025-12-31. This page shows 2 annual periods of income statement, balance sheet and cash flow figures normalized from IMPACT BIOMEDICAL INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

IMPACT BIOMEDICAL INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312022-12-31
Revenue$32.00K$50.00K
Cost of revenue$424.00KUnavailable
Gross profit-$392.00KUnavailable
Operating income-$4.28M-$3.40M
Net income-$11.84M-$7.26M
Research & development$340.00K$1.23M
Weighted-average diluted sharesUnavailableUnavailable
Pretax income-$14.45M-$7.88M
Income tax expense-$2.58M-$621.00K
Diluted EPS$-0.38$-0.10
Selling, general & administrative$873.00K$325.00K
General & administrativeUnavailableUnavailable
Selling & marketing$24.00KUnavailable

Balance

IMPACT BIOMEDICAL INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312022-12-31
Cash & equivalents$3.00K$2.00K
Total assets$17.40M$46.50M
Current assets$411.00K$122.00K
Total liabilities$1.85M$13.83M
Current liabilities$1.16M$10.59M
Total equity incl. NCI$15.56M$32.67M
Temporary (mezzanine) equityUnavailableUnavailable
Inventory$63.00KUnavailable
Accounts receivable$5.00KUnavailable
GoodwillUnavailable$25.09M
Long-term debtUnavailableUnavailable
Accounts payable$347.00K$539.00K

Cash flow

IMPACT BIOMEDICAL INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312022-12-31
Operating cash flow-$1.89M-$2.24M
Capital expendituresUnavailableUnavailable
Investing cash flow$3.00K-$349.00K
Financing cash flow-$109.00K$2.55M
Net change in cash-$2.00M-$44.00K
Stock-based compensation$13.00KUnavailable
Common dividends paidUnavailableUnavailable
Common share repurchasesUnavailableUnavailable
Depreciation & amortization$1.14M$1.11M

Derived

IMPACT BIOMEDICAL INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312022-12-31
Free cash flowUnavailableUnavailable
Gross margin-1225.0%Unavailable
Operating margin-13381.2%-6808.0%
FCF marginUnavailableUnavailable
SBC / revenue40.6%Unavailable
Current ratio0.35x0.01x
Revenue YoY growthUnavailableUnavailable
Net margin-36993.8%-14510.0%
R&D / revenue1062.5%2452.0%
CapEx / revenueUnavailableUnavailable
Long-term debt / equityUnavailableUnavailable
Effective tax rateUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IBO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-11View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.